-
Honokiol-Triggered Paraptosis in APL: mTOR and MAPK
2026-09-26
In NB4 acute promyelocytic leukemia cells, honokiol induced paraptosis-like death associated with reactive oxygen species, mitochondrial injury, endoplasmic reticulum stress, and proteasome impairment. The study links mTOR and MAPK signaling to this non-apoptotic response and cautions that increased LC3 and p62 do not, by themselves, establish autophagy.
-
Bazedoxifene for Osteoporosis: Evidence and Limits
2026-09-26
This 2019 review synthesizes phase III evidence on Bazedoxifene for postmenopausal osteoporosis, including long-term outcomes from randomized, placebo-controlled trials. It reports modest lumbar-spine bone mineral density gains and fewer vertebral fractures, while emphasizing that benefits for other fracture types are limited outside a high-risk subgroup.
-
Tankyrase Inhibitors Restrain HCC via Hippo Signaling
2026-09-25
Jia et al. report that the tankyrase inhibitors XAV-939 and G007-LK suppress growth of human hepatocellular carcinoma (HCC) cells alongside reduced YAP activity and increased AMOTL1/AMOTL2 protein levels. The study positions tankyrase–Hippo signaling as a preclinical research axis and suggests testing tankyrase inhibition in combination with MEK or AKT inhibition.
-
Catalpol in Cancer: Mechanisms and Evidence Review
2026-09-25
A 2025 review synthesizes preclinical research on catalpol, an iridoid glycoside studied for effects on cancer-cell growth, apoptosis, inflammation, and metastasis. Its findings connect several proposed anticancer mechanisms while highlighting the small, preclinical evidence base and the need for more consistent experimental and clinical evaluation.
-
MEG3–TGF-β1–PI3K/AKT Axis in NiO NP Fibrosis
2026-09-24
This study links reduced lncRNA MEG3 to TGF-β1-associated PI3K/AKT activation and collagen accumulation after nickel oxide nanoparticle exposure. Rat and A549-cell experiments, together with pathway-inhibitor and MEG3-overexpression tests, support a regulatory model of pulmonary fibrosis while leaving important questions about mechanism and human relevance open.
-
AT13387: Interpreting Hsp90 Inhibition in Cell-Death Assays
2026-09-24
AT13387 is a potent Hsp90 inhibitor for studying how client-protein destabilization changes cancer-cell survival. This article focuses on a practical distinction often missed in cell-death experiments: protein loss, apoptosis, and membrane rupture are different outcomes—and should be measured separately.
-
Remote Periosteal Distraction in Diabetic Wounds
2026-09-23
A rabbit study reports that osteotomy-free remote periosteal distraction improved ischemic diabetic foot wound repair and was associated with greater neovascularization and increased VEGF/VEGFR2-related responses. The findings identify periosteal mechanical stimulation as a potential less invasive alternative to osteotomy-based distraction, while leaving questions about causality, safety, durability, and clinical translation.
-
Oxaliplatin: SMC2/SMC4-Guided Cancer Assays
2026-09-22
Explore how Oxaliplatin can be used to connect platinum-induced DNA damage with SMC2/SMC4 biology. This article translates breast cancer findings into practical assay design, controls, and interpretation strategies.
-
PET Tracking of mRNA Vaccine Antigen Expression
2026-09-22
The reference study introduces an eDHFR–trimethoprim PET reporter system that measures where and how long an mRNA-encoded vaccine antigen is expressed in vivo. Its whole-body imaging results distinguish antigen production from delivery-vehicle biodistribution and support more evidence-based decisions about dosing, tissue targeting, and translational persistence.
-
Nicotine Signaling in Chronic Kidney Disease
2026-09-21
The review by Jain and Jaimes synthesizes clinical and experimental evidence that nicotine contributes to chronic kidney disease progression through non-neuronal nicotinic acetylcholine receptors, oxidative stress, hemodynamic changes, and profibrotic signaling. Its main practical value is mechanistic: it organizes how smoking-related nicotine exposure may worsen renal injury across disease models while identifying receptor blockade and pathway-specific experiments as potential research directions.
-
Human SAN–Cardiac Plexus Assembloids
2026-09-21
The reference study develops human pluripotent stem cell-derived assembloids that connect sinoatrial node, cardiac plexus, and atrial-like tissues to model neural regulation of pacemaker maturation. By combining electrophysiological analysis with human SAN spatial transcriptomics, it identifies a prosaposin–GPR37 signaling axis as a candidate mechanism linking intrinsic cardiac neurons to pacemaker development.
-
AZD8055: Practical mTOR Inhibitor Workflow
2026-09-20
AZD8055 is a selective ATP-competitive mTOR inhibitor for controlled studies of mTORC1 signaling, mTORC2 signaling, cancer-cell proliferation, and selected metabolic endpoints. This guide focuses on solvent handling, assay setup, and interpretation boundaries; it is not a substitute for clinical efficacy evidence or a water-soluble compound.
-
Bazedoxifene Repurposed as an Antimalarial
2026-09-19
The reference study shows that bazedoxifene, a third-generation selective estrogen receptor modulator used in postmenopausal osteoporosis, also inhibits Plasmodium development. Its activity was strongest against early ring-stage parasites and was associated with reduced hemozoin formation, supporting drug repurposing while highlighting sex-dependent differences between mouse efficacy and erythrocyte-based assays.
-
Bazedoxifene Research Workflows and Applications
2026-09-19
Bazedoxifene is a selective estrogen receptor modulator for studying bone protection, estrogen receptor signaling, and ER-independent antimalarial activity. This workflow-focused guide connects validated osteoporosis models with parasite-stage and hemozoin assays while emphasizing formulation, controls, and interpretation limits.
-
Bazedoxifene for Osteoporosis: Evidence and Limits
2026-09-18
The 2019 drug evaluation positions Bazedoxifene as a tissue-selective estrogen receptor modulator with modest lumbar-spine bone mineral density benefits and meaningful vertebral-fracture protection in postmenopausal osteoporosis. Its main practical value is the integrated assessment of long-term efficacy, tolerability, and patient-risk selection, while the review also emphasizes that Bazedoxifene has not demonstrated broad superiority over established antiresorptive therapies.